Pharm-Olam, a global mid-sized clinical research organization, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to join their Clinical Studies Network. Under the terms of the contract, Pharm-Olam will provide routine and/or response clinical services for the advanced development of medical countermeasures.
Pharm-Olam's contract with BARDA is an indefinite-delivery, indefinite-quantity or IDIQ agreement for Clinical Trial Planning and Execution or CTPE services with application possibilities encompassing Phases I-IV. The contract has a minimum performance period of two years, stretching to a maximum of five years, with a $250M total contract ceiling value.
To read the full release, click here.
